论文部分内容阅读
作者回顾分析了1926例白血病和326例再生障碍性贫血患者骨髓移植(BMT)后继发癌的发生率.其中同基因体152例,异基因HLA相合或部分相合家属成员供体1980例,HLA表示相合无关供体13例,自身BMT101例.35例移植后1.5月-13.9年(中数1.0年)诊断为继发性癌症,年龄2-58岁(中数21岁).16例非何杰金淋巴瘤(NHL,2例T细胞型,11例与EB病毒相关,3例不能分类),6例白血病(2例于宿主细胞,与原白血病细胞形态不同,4例累及供者细胞),
The authors retrospectively analyzed the incidence of secondary cancer after bone marrow transplantation (BMT) in 1926 leukemias and 326 patients with aplastic anemia, of which 152 were with or without genic HLA, and 1980 were HLA-matched donors Thirteen patients with unrelated donors and 101 patients with their own BMT were diagnosed as secondary cancers from 1.5 months to 13.5 years after transplantation (median 1.0 years), ranging in age from 2-58 years (median 21) (NHL, 2 T-cell types, 11 associated with Epstein-Barr virus, 3 not classifiable), 6 leukemia (2 in host cells, different from original leukemia cells and 4 involving donor cells)